Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

Launched by DO HYUN PARK · Jun 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking for new ways to detect pancreatic cancer early by studying fluids collected from the small intestine (duodenum) during a routine procedure called an endoscopy. Pancreatic cancer is a serious disease that is often found too late, making treatment difficult. This study hopes to find markers, or signs, in the fluid that could help doctors diagnose pancreatic cancer sooner, which may improve treatment options and outcomes.

People who might join this study are adults over 19 who need an endoscopy or related procedure for medical reasons. This includes those who have been diagnosed with pancreatic cancer or are suspected to have it based on imaging tests, as well as people with other pancreatic conditions like cysts or inflammation, or even those without any pancreatic disease. Participants will have fluid collected during their scheduled procedure, and this will be analyzed to search for potential early signs of pancreatic cancer. The study does not involve any extra invasive procedures beyond the planned endoscopy, but some people won’t be able to join if they have certain health issues that make the procedure unsafe.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Among the patients requiring gastro-duodenal endoscopy, endoscopic ultrasound, or ERCP for medical purposes, the pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.
• • 1. Be at least 19 years old.
• • 2. Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
• • 3. A biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC).
• • 4. Suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.
• • The non-pancreatic cancer group should meet the criteria numbered 1, 2, and either 3 or 4.
• • 1. Be at least 19 years old.
• • 2. Have completed the informed consent for planned upper endoscopy, endoscopic ultrasound, or endoscopic retrograde cholangiopancreatography before the duodenal fluid collection.
• • 3. Patients with pancreatic cystic tumors or patients with acute or chronic pancreatitis.
• • 4. No evidence of a pancreatic disease.
• Exclusion Criteria:
• The exclusion criteria for the pancreatic cancer and the non-pancreatic cancer groups will be:
• • 1. Innate or post-surgical anatomy that precludes direct sampling of duodenal fluid.
• • 2. Hemodynamically unstable and unable to have an endoscopy performed.
• • 3. A large amount of ascites fluid that is not controlled and unable to have an endoscopy performed.
• • 4. A coagulation disorder that cannot be corrected and unable to have an endoscopy performed.